Scynexis, a drug discovery and development company, directs medicinal chemistry, advanced biological screening, bioanalytical and ADMET activities towards Merial’s animal health discovery efforts.
Scynexis president and CEO Yves Ribeill said that the company is pleased to earn another important research milestone through their valued partnership with Merial.
"This is the fourth consecutive milestone we have reached for delivering significant, innovative animal health development candidates to Merial under the agreement," Ribeill said.
Merial Discovery and Research head Christian Miculka said that Merial is delighted to see this latest success resulting from the pharmaceutical discovery collaboration with Scynexis.